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The type and the extent of tissue damage inform the
prognosis of chronic kidney disease (CKD), but kidney biopsy
is not a routine test. Urinary tests that correlate with specific
histological findings might serve as surrogates for the kidney
biopsy. We used immunoblots and ARCHITECT-NGAL
assays to define the immunoreactivity of urinary neutrophil
gelatinase–associated lipocalin (NGAL) in CKD, and we used
mass spectroscopy to identify associated proteins. We
analyzed kidney biopsies to determine whether specific
pathological characteristics associated with the monomeric
NGAL species. Advanced CKD urine contained the NGAL
monomer as well as novel complexes of NGAL. When these
species were separated, we found a significant correlation
between the NGAL monomer and glomerular filtration rate
(r¼0.53, Po0.001), interstitial fibrosis (mild vs. severe
disease; mean 54 vs. 167lg uNGAL/g Cr, Po0.01), and
tubular atrophy (mild vs. severe disease; mean 54 vs. 164lg
uNGAL/g Cr, Po0.01). Monospecific assays of the NGAL
monomer demonstrated a correlation with histology that
typifies progressive, severe CKD.
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Over the next decade, the number of patients reaching end
stage renal disease (ESRD) will double as a result of the
progression of chronic diseases of the kidney (CKD).1 The
rate of progression however is difficult to predict by currently
available tests. Serum creatinine measurements are con-
founded by age, muscle mass, gender, race, medications,
hydration status, and extrarenal clearance.2 Proteinuria is a
critical cause of disease progression, yet progression may
occur even in its absence.3 Tubulointerstitial disease perhaps
best presages worsening CKD,3 however, kidney biopsy is not
practical for routine use and generally does not sample
medullary tubules. Here, we evaluated relationships between
a urinary protein and biopsy findings in a CKD cohort.
Neutrophil gelatinase–associated lipocalin (NGAL) gene
product (Lcn2, Siderocalin) is a ‘monomeric’ protein
(23–26 kDa)4 that is induced by the triggers of acute kidney
injury (AKI).4–6 In contrast, NGAL is only marginally
increased during periods of slowly progressive CKD,4,7whereas
progressive disease,8 advancing HIVAN,9 diabetes,10 and end-
stage11–13 upregulate NGAL in the absence of an acute event. It
is important to determine whether a specific molecular form
of urinary NGAL identifies a specific histological character-
istic, implying not only that it may serve as a surrogate
marker, but also that it participates in a pathway modulating
the growth of damaged tubules12,14 and defense of the urinary
tract by scavenging iron.15
RESULTS
High-molecular weight NGAL species identified with
cation-exchange and gel filtration
To determine the molecular form of NGAL, we analyzed the
urine of 99 patients by immunoblot and found a recurrent
pattern of immunoreactivities. The majority of immuno-
reactive NGAL was ‘monomeric’, but additional reactivities
were found at 4250, 125, 75 kDa in non-reducing gels. The
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75-kDa species was potentially trimeric NGAL, and the 125-
kDa species was potentially NGAL-MMP-916 but the 4250-
kDa immunoreactive band was a novel complex. To identify
this protein, we fractionated the urine of a stage 5 patient
using cation-exchange and gel filtration. Mass methodology
identified the 4250-kDa complex as the secretory compo-
nent of the polymeric immunoglobulin receptor (peptides:
LVSLTLNLVTR; ILLNPQDKDGSFSVVITGLR; and QGHFY-
GETAAVYVAVEER) together with a2-macroglobulin. Upon
reduction, monomeric NGAL dissociated from the complex
(Figure 1).
As the monomeric form of NGAL has been specifically
associated with epithelial stress,4,5 we decided to quantify this
species with ARCHITECT-NGAL (Abbott) assays,7 which
correlated with the detection of the monomer by immuno-
blots (r¼ 0.69, Po0.001), demonstrating the same rank
order and producing nearly identical statistical differences
(analysis of variance) across different diagnoses (o0.05,
ARCHITECT-NGAL ando0.01, immunoblot). The ARCHI-
TECT-NGAL demonstrated 3.8% (s.d. 7.7%) of total
immunoreactivity was 4100 kDa, but with variable con-
tribution (0–41.9%).
Correlations between NGAL levels and histological diagnoses
Accurate quantification of the monomer permitted a
comparison with clinical and pathological characteristics at
the time of the biopsy (Supplementary Table S1 online).
Rapidly progressive glomerulonephritis (n¼ 3), dialysis
(n¼ 10), and AKI were excluded at the time of enrollment.
Six percent of our cohort had been on steroids before biopsy.
On an average, the cohort was male (70%), age 52.2 years
(s.d. 16.8) with a glomerular filtration rate (GFR)
57.7ml/min (s.d. 34.5); hypertension was common (69.7%,
mean 138.7mmHg s.d. 22.0/81.9mmHg s.d. 11.3) but
diabetes was present in only 18.2%. Pathological diagnoses
were diverse: nephrotic syndromes (49.5%: membranous,
focal segmental glomerulosclerosis, minimal change disease,
and amyloidosis), nephritic syndromes (31%: immun-
oglobulin (Ig)A and lupus nephropathies, membranoprolif-
erative and mesangial proliferative glomerulonephritides,
and fibrillary and immunotactoid nephritis), diabetic
nephropathy (10%), and other diagnoses (9%: nephroangio-
sclerosis, ESRD, light-chain nephritis, myeloma, and isolated
chronic tubulointerstitial nephritis).
Although the monomer appeared most elevated in diabetics
(Supplementary Table S1 online), statistical significance was
demonstrated with measures of disease chronicity, rather than
specific diagnoses. For example, the monomer correlated
inversely with GFR (r¼0.53, Po0.001) and directly with the
chronicity index (P¼ 0.003) as reflected by a dose-dependent
relationship (Figure 2). Additionally, the monomer specifically
associated with both tubular atrophy (P¼ 0.002) and inter-
stitial fibrosis (P¼ 0.006). Moderate or severe fibrosis or
atrophy were associated with three- to four-fold higher levels of
NGAL monomer (each Po0.01) compared with mild or
absent fibrosis or atrophy (Table 1, Figure 3). Similarly, fibrous
crescents (P¼ 0.001) and global glomerulosclerosis (P¼ 0.037)
were highly correlated with the monomer, both suggestive of
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Figure 1 |Urine was fractionated by cation exchange
chromatography and fractions containing immunoreactive
neutrophil gelatinase–associated lipocalin (NGAL) species
were then separated by filtration chromatography (left
panels). Note that the monomer (23–26 kDa, fractions (Fxs) 24–32)
comprised the majority of immunoreactive NGAL, but additional
species can be found at 75 kDa (fractions 19–23), 125 kDa
(fractions 15–18), and 4250 kDa (fractions 9–11). When the latter
were pooled and reduced, the only immunoreactive species was
the monomer (right). These data show that in advanced chronic
kidney disease (CKD), a proportion of NGAL is associated with
other proteins.
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Figure 2 |uNGAL associations in chronicity, activity indices,
GFR, and proteinuria. Urinary neutrophil gelatinase–associated
lipocalin (uNGAL) monomer according to (a) chronicity and
(b) activity indices of kidney biopsies concurrent with the urine
samples. *Po0.01 compared with scores 8–11. uNGAL monomer
according to (c) glomerular filtration rate (GFR) and (d) proteinuria.
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chronic damage. For example, 96% of patients with fibrous
crescents had some degree of tubulointerstitial disease, 35%
moderate or severe. In all, 99% of patients with global
glomerulosclerosis demonstrated tubulointerstitial disease,
44% of which had moderate or severe levels. Diabetics may
have somewhat higher levels of NGAL because 75% demon-
strated moderate-to-severe interstitial fibrosis (vs. nephrotic
syndrome (26%), P¼ 0.002; vs. nephritic syndrome (9%),
P¼ 0.002) and tubular atrophy (vs. nephrotic syndrome
(28%), P¼ 0.001; vs. nephritic syndrome (16%), P¼ 0.002)
in excess of other forms of CKD (without significant difference
in GFR). The monomer was also associated with proteinuria
(r¼ 0.27, P¼ 0.008), albeit this association weakened further
when adjusted for GFR (r¼ 0.20, P¼ 0.06).
In contrast, the monomer was either associated with
activity indices of glomerular disease (P¼ 0.847, Figure 2),
particularly cellular changes such as glomerular leukocyte
infiltrates (P¼ 0.34), mesangial proliferation (P¼ 0.616),
cellular crescents (P¼ 0.569), fibrinoid necrosis (P¼ 0.168),
nor strongly with monocellular-predominant interstitial
infiltrates (P¼ 0.056), while there was an association with
mesangial matrix expansion (P¼ 0.004) implying that the
monomer was better associated with chronic rather than
acute cellular changes.
Neutrophils and macrophages may be present in the
interstitium and contribute to NGAL but our pathological
analysis failed to associate the monomer with interstitial
cellular infiltrates including the dominant lympho-mono-
cytic interstitial infiltrate. Additionally, isoelectric point
analysis of dithiothreitol-reduced samples demonstrated
similar isoelectric points for monomeric NGAL in patients
with AKI or CKD (pI: 7.1, 8.2, 8.5, and 8.8–9.2), whereas
neutrophil NGAL demonstrated a different pattern of
alkaline-shifted species (pI: 8.5–9.2). Urinary myeloperox-
idase, a protein released from neutrophils, also did not
correlate with NGAL monomer in the current (R2¼ 0.087) or
in a previously identified cohort (R2¼ 0.0092) whereas
NGAL and myeloperoxidase were highly correlated in
isolated blood neutrophils (R2¼ 0.99).
DISCUSSION
In summary, although the monomer of NGAL was the
predominant, if not the only form expressed in AKI, CKD
urine consistently demonstrated additional immunoreactiv-
ities including the presence of known and novel HMW
complexes formed by disulfide linkages. The latter might
form in thick ascending limb epithelia or in the urinary space
because both the extracellular secretory component of
polymeric IgR (68 kDa) and NGAL are secreted from the
luminal membrane of the TAL.17 a-2-Macroglobulin can also
be found in CKD urine18 whereas its receptor LRP1/CD91 is
found in the tubulointerstitial compartment where it may
concentrate and endocytose a2-macroglobulin.19 Perhaps
these transport proteins provide a clearance mechanism,
rather than directly depicting epithelial damage. In this light,
determining the site of complex formation will help identify
their clinical significance, as recently demonstrated by the
Table 1 | Relationship between clinical characteristics, GFR, proteinuria, NGAL monomer, and chronic histological
characteristics
Global glomerulosclerosis Atherosclerosis Interstitial fibrosis Tubular atrophy
None (n=32)
Present
(n=67)
None mild
(n=42)
Moderate
severe (n=57)
None mild
(n=68)
Moderate
severe (n=31)
None mild
(n=68)
Moderate
severe (n=31)
Female (%) 34.4 26.9 35.7 24.6 32.4 22.6 33.8 19.4
Age (years) 48.1 (17.9) 52.4 (16.3) 46.0 (16.9) 55.9 (15.8) 49.6 (17.3) 56.2 (15.4) 48.8 (16.7) 58.1 (15.7)
HTN (%) 50* 74.6 52.4* 77.2 54.4** 93.5 55.9** 90.3
Diabetes (%) 12.5 16.4 7.1 21.1 7.4** 32.3 7.4** 32.3
PCreatinine
(mg/dl)
1.1 (0.5)** 1.9 (1.3) 1.2 (0.5)** 2.0 (1.4) 1.3 (0.6)** 2.5 (1.5) 1.3 (0.7)** 2.4 (1.6)
eGFR (ml/min) 81.7 (31.6)** 53.2 (29.1) 78.6 (31.5)** 50.1 (28.2) 73.4 (30.3)** 38.4 (23.5) 72.1 (31.5)** 41.3 (24.2)
Proteinuria
(g/24 h)
7.0 (6.3) 5.6 (5.8) 5.9 (6.0) 6.2 (6.0) 5.5 (5.0) 7.3 (7.8) 5.7 (5.8) 6.8 (6.5)
Mean uNGAL
(mg/g
creatinine)
53.4 (101.1)* 105.8 (232.0) 49.9 (80.1) 117.8 (252.3) 54.1 (111.0)** 167.1 (309.8) 54.1 (112.0)** 163.6 (305.2)
Abbreviations: eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; HTN, hypertension; NGAL, neutrophil gelatinase–associated lipocalin; PCreatinine,
plasma creatinine; uNGAL, urinary NGAL.
*Po0.05 compared with present.
**Po0.01 compared with present.
20 ng/ml 220 ng/ml
Figure 3 | Illustrative kidney biopsies of two patients with
membranous nephropathy. Urinary neutrophil
gelatinase–associated lipocalin (NGAL) levels are indicated. Note
the widened interstitial compartments, tubular flattening, and
tubular dilation in the more advanced cases that expresses a 10-
fold higher level of NGAL. Mason trichrome stain. Bar¼ 50mm.
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identification of the dimer in neutrophils and the monomer
in epithelia.20
Most importantly, this study showed that monomer
reflects the severity of tubulointerstitial, rather than glomer-
ular-specific pathologies.3 Tubulointerstitial genes (Scara5,
Col6a13, Nfix, Acvrl1, and myogenic proteins; J. Barasch,
unpublished) induced by NGAL in rat kidney mesenchyme
are compatible with this hypothesis. These data are novel
because they suggest that the monomer is expressed in many
common forms of advanced CKD, whereas previously
characterized patterns of NGAL expression were disease-
restricted including the HIVAN microcyst,9 and the TAL and
a-intercalated cell in AKI.5 Consequently, we propose that
the association of NGAL with CKD may be better appreciated
by specific measurements of the monomer, as NGAL
complexes 4100 kDa contribute variably to total immuno-
reactivity and potentially involve proteins derived from non-
renal cell types. The same type of molecular analysis might
apply to other urinary ‘biomarkers.’
MATERIALS AND METHODS
Urine collection and NGAL measurement
The University of Parma and Columbia approved the study;
informed consent was obtained. Patients (1/2005–4/2008) were
418 years old. Urine was centrifuged (12,000 r.p.m.,  10min),
stored (between 2 months and 3 years at 801C) and analyzed in
batch with non-reducing 4–15% polyacrylamide gels (Bio-Rad
Laboratories, Hercules, CA) and monoclonals (1:1000; Antibody-
Shop, Gentofte, Denmark) using standards (0.3–3 ng) of human
NGAL by workers blinded to biopsy data. ARCHITECT-NGAL
assays were performed at the Cincinnati Children’s Hospital.
High-molecular weight NGAL evaluation
High-molecular weight immunoreactivity was evaluated by filtering
the urine (Microcon Ultracel YM-100, 100 kDa filter; Millipore,
Billerica, MA), followed by MiniS (Mes 20mM, pH6.0 þ gradient of
NaCl, 0.5 M) and Superdex200 (PBS) chromatography. NGAL-
containing complexes were digested with trypsin, batch fractionated
on a Poros 50 R2 RP micro-tip, and the resulting peptide pools were
analyzed by MALDI-reTOF, using a BRUKER UltraFlex TOF/TOF
instrument (Bruker Daltonics; Bremen, Germany).21 Selected experi-
mental masses (m/z) were taken to search human non-redundant
protein database (NCBI) utilizing the Mascot Peptide Mass
Fingerprint,22 version 2.3.01, with a mass accuracy restriction better
than 35 p.p.m., and maximum allowed one cleavage site missed per
peptide. To confirm PMF results with scores o40, mass spectro-
metric sequencing of selected peptides was done by MALDI-TOF/
TOF (MS/MS) reanalysis, using the UltraFlex instrument in ‘LIFT’
mode. Fragment ion spectra were taken to search NR using Mascot
MS/MS Ion Search program.22 Isoelectric focusing (Kendrick Labs,
Madison, WI)23 utilized polyvinylidene difluoride immunoblotting.
Pathological analysis of biopsy specimens
Kidney biopsies (obtained as part of routine care in all subjects at
the time of urine sampling) were formalin-fixed, paraffin-
embedded, and sections stained with hematoxylin/eosin, Masson’s
trichrome stain, silver methenamine, and periodic acid–Schiff. IgG,
IgM, IgA, C3, and fibrinogen deposition were detected by
immunoflourescence. Biopsies were graded by two independent
pathologists blinded to both diagnosis and NGAL level. Glomerular,
tubular, interstitial, and vascular lesions were scored as 0, absent;
1, mild; 2, moderate; and 3, severe.
Measurement of other biomarkers
The sensitivity of myeloperoxidase enzyme-linked immunosorbent
assay (Alpco, Salem, NH) was determined using serial dilutions
of neutrophils isolated from citrated blood.24 Although the enzyme-
linked immunosorbent assay was sensitive to a 0.01 dilution,
immunoblot detection of NGAL in the same sample was consistent
only to 0.1 , indicating that these assays favored detection of
myeloperoxidase compared with NGAL.
GFR was estimated by the MDRD formula,25 urinary creatinine
measured by QuantiChrom Creatinine Assay Kit (BioAssay Systems,
Hayward, CA), serum creatinine by Jaffe, and urinary protein by
nephelometry.
Statistical analysis
Statistical analysis (SPSS v16.0, Chicago, IL): continuous variables
were log-transformed and compared by Student’s t-test for unequal
variances or analysis of variance. Categorical variables were
compared by w2. The null hypothesis was rejected at Po0.05. Data
were represented as the meanþ s.d..
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